Hydroxychloroquine and azithromycin as a treatment of COVID-19

Fanin, Alice; Calegari, Jessica; Beverina, Anna; Tiraboschi, S.

doi:10.1007/s11739-020-02388-y

Cited by 12 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context of CRS, patients could take advantage of O 3 gas anti-inflammatory and immune-modulatory properties. On this basis, we performed a case–control study in patients with COVID-19 to assess O 3 -autohemotherapy as adjuvant therapy, in addition to the prescription of standard treatments used such as hydrossi-chloroquine, azithromycin, antivirals (lopinavir/ritonavir, darunavir/cobicistat) and immunomodulating agents (steroids, tocilizumab) [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience

Tascini¹,

Sermann

Pagotto³

et al. 2020

Intern Emerg Med

View full text Add to dashboard Cite

The emerging outbreak of the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide. We prescribed some promising medication to our patients with mild to moderate pneumonia due to SARS-CoV-2, however such drugs as chloroquine, hydrossichloroquine, azithromycin, antivirals (lopinavir/ritonavir, darunavir/cobicistat) and immunomodulating agents (steroids, tocilizumab) were not confirmed as effective against SARS-CoV2. We, therefore, started to use auto-hemotherapy treated with an oxygen/ozone (O 2 /O 3 ) gaseous mixture as adjuvant therapy. In Udine University Hospital (Italy) we performed a case–control study involving hospitalized adult patients with confirmed COVID-19 with mild to moderate pneumonia. Clinical presentations are based upon clinical phenotypes identified by the Italian Society of Emergency and Urgency Medicine (SIMEU—Società Italiana di Medicina di Emergenza-Urgenza) and patients that met criteria of phenotypes 2 to 4 were treated with best available therapy (BAT), with or without O 3 -autohemotherapy. 60 patients were enrolled in the study: 30 patients treated with BAT and O 2 /O 3 mixture, as adjuvant therapy and 30 controls treated with BAT only. In the group treated with O 3 -autohemotherapy plus BAT, patients were younger but with more severe clinical phenotypes. A decrease of SIMEU clinical phenotypes was observed (2.70 ± 0.67 vs. 2.35 ± 0.88, p = 0.002) in all patients during hospitalization but this clinical improvement was statistically significant only in O 3 -treated patients (2.87 ± 0.78 vs. 2.27 ± 0.83, p < 0.001), differently to the control group (2.53 ± 0.51 vs. 2.43 ± 0.93, p = 0.522). No adverse events were observed associated with the application of O 2 /O 3 gaseous mixture. O 2 /O 3 therapy as adjuvant therapy could be useful in mild to moderate pneumonia due to SARS-CoV-2. Randomized prospective study is ongoing [Clinical Trials.gov ID: Z7C2CA5837].

show abstract

Section: Introductionmentioning

confidence: 99%

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience

Tascini¹,

Sermann

Pagotto³

et al. 2020

Intern Emerg Med

View full text Add to dashboard Cite

show abstract

“…Recently, combination therapy with HCQ and AZM has become one of the most favoured treatment regimens among medical professionals [26] , [27] , [28] . Studies have shown that the combination of HCQ and AZM can reinforce the efficacy of HCQ [28 , 29] . Gautret et al.…”

Section: Discussionmentioning

confidence: 99%

Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial

Sekhavati

Jafari

SeyedAlinaghi

et al. 2020

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

show abstract

“…Azithromycin, a macrolide antibiotic with excellent tissue penetration and anti-inflammatory effects, downregulates pathways involving serine proteases TMPRSS2 and TMPRSS11D required for SARS-CoV-2 activation, indicating that azithromycin may hinder SARS-CoV-2 infection (135). In combination with hydroxychloroquine, azithromycin was shown to inhibit the replication of SARS-CoV-2 (136). As of 28th April 2020, there are 21 clinical trials registered on ClinicalTrials.gov for azithromycin related to COVID-19 (137).…”

Section: Rbd-targeting Antibodiesmentioning

confidence: 99%

Confronting the threat of SARS‑CoV‑2: Realities, challenges and therapeutic strategies (Review)

2020

View full text Add to dashboard Cite

Hydroxychloroquine and azithromycin as a treatment of COVID-19

Cited by 12 publications

References 5 publications

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience

Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial

Confronting the threat of SARS‑CoV‑2: Realities, challenges and therapeutic strategies (Review)

Contact Info

Product

Resources

About